DB604: SARS-CoV-2 PLpro (Papain-like Protease)

Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several proteases including papain-like protease (PL2PRO; PLPro); this key enzyme along with 3CL-protease drives the early stage of infection by processing a large viral polypeptide into functional enzymes. SARS-CoV-2 PLPro shares 82% in protein sequence identity with PLPro from SARS-CoV. The SARS-CoV-2 PLPro was shown to have a deubiquitinating activity. Subsequently, it was shown that PLPro is also a deISGylase. PLPro cleaves ISG15 and Ubiquitin from synthetic substrates with high and low efficiency, respectively. PLPro represents an antiviral drug target for counteracting SARS-CoV-2 infections.

Info

Species	SARS-CoV-2
Source	E. coli
Tag	None
Molecular Weight	37 kDa
Quantity	100 µg
Concentration	Variable
Formulation	50 mM Tris-HCl pH 8.5, 150 mM NaCl, 1 mM DTT, 10% glycerol
Storage	-80°C, avoid freeze/thaw cycles